BR112022002784A2 - Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo - Google Patents
Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmoInfo
- Publication number
- BR112022002784A2 BR112022002784A2 BR112022002784A BR112022002784A BR112022002784A2 BR 112022002784 A2 BR112022002784 A2 BR 112022002784A2 BR 112022002784 A BR112022002784 A BR 112022002784A BR 112022002784 A BR112022002784 A BR 112022002784A BR 112022002784 A2 BR112022002784 A2 BR 112022002784A2
- Authority
- BR
- Brazil
- Prior art keywords
- salts
- compositions
- methods
- tetracyclic compounds
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886621P | 2019-08-14 | 2019-08-14 | |
| US201962946774P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/046329 WO2021030671A1 (en) | 2019-08-14 | 2020-08-14 | Tetracyclic compounds and their salts, compositions, and methods for their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022002784A2 true BR112022002784A2 (pt) | 2022-08-09 |
Family
ID=74568302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022002784A BR112022002784A2 (pt) | 2019-08-14 | 2020-08-14 | Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210046071A1 (https=) |
| EP (1) | EP4013421A4 (https=) |
| JP (1) | JP7566010B2 (https=) |
| KR (1) | KR20220130085A (https=) |
| CN (1) | CN114599368A (https=) |
| AU (1) | AU2020328590B2 (https=) |
| BR (1) | BR112022002784A2 (https=) |
| CA (1) | CA3151112A1 (https=) |
| IL (1) | IL290626A (https=) |
| PH (1) | PH12022550360A1 (https=) |
| TW (1) | TW202114694A (https=) |
| WO (1) | WO2021030671A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7017509B2 (ja) | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| CN112334133A (zh) | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
| CN114409681A (zh) * | 2022-03-18 | 2022-04-29 | 信义核新(北京)生物科技有限公司 | 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7928100B2 (en) * | 2007-10-05 | 2011-04-19 | Cylene Pharmaceuticals, Inc. | Quinolone analogs and methods related thereto |
| US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
| ES2754207T3 (es) * | 2013-11-28 | 2020-04-16 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Inhibidores de la ARN polimerasa I y usos de los mismos |
| JP7017509B2 (ja) * | 2015-11-20 | 2022-02-08 | センワ バイオサイエンシズ インコーポレイテッド | がんを治療するための四環式キノロン類似体の併用療法 |
| US9957282B2 (en) * | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| JP2018537486A (ja) * | 2015-12-14 | 2018-12-20 | センワ バイオサイエンシズ インコーポレイテッド | キノロン類似体及びその塩の結晶形 |
| CN112334133A (zh) * | 2018-02-15 | 2021-02-05 | 生华生物科技股份有限公司 | 喹诺酮类似物及其盐、组合物及其使用方法 |
-
2020
- 2020-08-14 EP EP20851932.2A patent/EP4013421A4/en active Pending
- 2020-08-14 PH PH1/2022/550360A patent/PH12022550360A1/en unknown
- 2020-08-14 CA CA3151112A patent/CA3151112A1/en active Pending
- 2020-08-14 TW TW109127804A patent/TW202114694A/zh unknown
- 2020-08-14 CN CN202080069508.0A patent/CN114599368A/zh active Pending
- 2020-08-14 BR BR112022002784A patent/BR112022002784A2/pt not_active Application Discontinuation
- 2020-08-14 AU AU2020328590A patent/AU2020328590B2/en active Active
- 2020-08-14 JP JP2022509131A patent/JP7566010B2/ja active Active
- 2020-08-14 KR KR1020227008247A patent/KR20220130085A/ko not_active Withdrawn
- 2020-08-14 US US16/993,840 patent/US20210046071A1/en active Pending
- 2020-08-14 WO PCT/US2020/046329 patent/WO2021030671A1/en not_active Ceased
-
2022
- 2022-02-14 IL IL290626A patent/IL290626A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021030671A1 (en) | 2021-02-18 |
| JP2022544559A (ja) | 2022-10-19 |
| US20210046071A1 (en) | 2021-02-18 |
| IL290626A (en) | 2022-04-01 |
| JP7566010B2 (ja) | 2024-10-11 |
| AU2020328590A1 (en) | 2022-03-10 |
| PH12022550360A1 (en) | 2023-02-27 |
| KR20220130085A (ko) | 2022-09-26 |
| AU2020328590B2 (en) | 2026-03-26 |
| EP4013421A1 (en) | 2022-06-22 |
| EP4013421A4 (en) | 2023-08-23 |
| TW202114694A (zh) | 2021-04-16 |
| CA3151112A1 (en) | 2021-02-18 |
| CN114599368A (zh) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022002784A2 (pt) | Compostos tetracíclicos e sais do mesmo, composições e métodos para uso do mesmo | |
| BR112015012366A2 (pt) | antagonistas de cxcr7 | |
| BR112013032928A2 (pt) | "derivados de maitansinoide com ligante de peptídeo e conjugados dos mesmos, composição farmacêutica que os compreende e uso dos mesmos" | |
| BR112022008919A2 (pt) | Composto e método para tratamento de distúrbios psiquiátrico ou neurológico | |
| BR112015022337A2 (pt) | composição sinérgica, método para o tratamento de dislipidemia, hipertrigliceridemia e diabetes mellitus, uso de um composto, composição farmacêutica, processo para a preparação da composição farmacêutica e sal | |
| BR112015006075A2 (pt) | composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina | |
| BRPI0906444A8 (pt) | compostos de 4-piridinona e seu uso para câncer | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| TR201900306T4 (tr) | Mek inhibitörlerini kullanma yöntemleri. | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| BR112012026289A2 (pt) | composto orgânico para uso no tratamento de câncer do fígado | |
| EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
| TN2009000400A1 (en) | Methods of treating cancer using pyridopyrimidininone inhibitors of pi3k alpha | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| BR112013032770A2 (pt) | composições farmacêuticas compreendendo antibiótico beta-lactama, sulbactama e inibidor de beta-lactamase | |
| BRPI0518360A2 (pt) | composto e sais farmaceuticamente aceitÁveis do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar um composto ou um sal farmaceuticamente aceitÁvel do mesmo | |
| BR112015013450A8 (pt) | compostos bicíclicos, uso dos compostos, composição farmacêutica, complexo molecular e processo para preparação dos referidos compostos | |
| GEP20125459B (en) | Compounds for inhibiting mitotic progression | |
| BRPI0618479A2 (pt) | pirrolpiridinas composição farmacêutica que as contém | |
| BR112022011690A2 (pt) | Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, método para o tratamento ou profilaxia de câncer, método para o tratamento ou profilaxia de câncer de pulmão de células não pequenas e invenção | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| PH12021551157A1 (en) | Ketamine pamoate and use thereof | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |